Goldsmith M A, Slavik M, Carter S K
Cancer Res. 1975 May;35(5):1354-64.
The mouse, dog, and monkey toxicity data on 30 drugs was retrospectively analyzed in comparison with the actual clinical dose schedules used in man. Animal dose schedules were converted to the human schedule and comparisons were made of the human dose versus the large animal toxic dose low, toxic dose high, and lethal dose, the lethal doses for 10% and 90% of normal mice, and the optimal dose in tumor-bearing mice. If the starting dose in Phase 1 clinical trials had been selected by calculating one-third of the toxic dose low (in mg/sq m) in the most sensitive large animal species, 5 of the 30 drugs would have produced significant toxicity in the first patient. The lethal doses for 10 and 90% of normal mice and the optimal dose in L1210-bearing mice were found to offer good quantitative prediction of human toxicity. Determination of a safe and practical starting dose for Phase 1 studies should take into account not only dog and monkey data but also toxicology data in normal and tumor-bearing mice.
回顾性分析了30种药物的小鼠、狗和猴子毒性数据,并与人类实际使用的临床剂量方案进行比较。将动物剂量方案换算为人类剂量方案,并比较人类剂量与大型动物低毒性剂量、高毒性剂量和致死剂量,正常小鼠10%和90%的致死剂量,以及荷瘤小鼠的最佳剂量。如果一期临床试验的起始剂量是通过计算最敏感的大型动物物种的低毒性剂量(mg/平方米)的三分之一来选择的,那么30种药物中的5种会在首例患者中产生显著毒性。发现正常小鼠10%和90%的致死剂量以及L1210荷瘤小鼠的最佳剂量能很好地定量预测人类毒性。确定一期研究的安全实用起始剂量不仅应考虑狗和猴子的数据,还应考虑正常和荷瘤小鼠的毒理学数据。